Patents by Inventor Monicka C. Jones

Monicka C. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Accelerated treatment of COVID-19 and SAR's type viruses
    Publication number: 20220226330
    Abstract: Inhalation Via Nebulized Aerosol of Designed solution mixture of 1.8 to 3.7% Hypertonic saline 70 to 85% Ethanol as solvent alternating with 10 milliliters 50 to 90% Theobromine alternatively I.V. Theobromine “c7H8N4O2” infusion alternating with inhaled nebulized exogenous Pulmonary surfactant replacement. The inhalation alternating as an I.V. solution or 1.8% to 2.2% hypertonic solution in Theobromine as 450 mg to 650 mg. in Ethanol, twice daily for advanced COVID-19, SARS patients.
    Type: Application
    Filed: December 13, 2021
    Publication date: July 21, 2022
    Inventor: Monicka C. Jones
  • Accelerated treatment of COVID-19 and SAR's type viruses
    Patent number: 11207326
    Abstract: The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: December 28, 2021
    Inventors: Binyomin A. Cohen, Monicka C. Jones
  • Accelerated Treatment of COVID-19 and SAR's Type Viruses
    Publication number: 20210369719
    Abstract: The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily.
    Type: Application
    Filed: May 26, 2020
    Publication date: December 2, 2021
    Inventors: Binyomin A. Cohen, Monicka C. Jones